Company Filing History:
2 out of 1,556 
1 out of 3,540 
Years Active: 2013-2018
Title: Myriam Aouadi: Innovator in Diabetes Treatment and Nucleic Acid Delivery
Introduction
Myriam Aouadi is a prominent inventor based in Worcester, MA (US). She has made significant contributions to the fields of diabetes treatment and nucleic acid delivery. With a total of 2 patents, her work is paving the way for innovative therapeutic solutions.
Latest Patents
Aouadi's latest patents include "Glucan-encapsulated siRNA for treating type 2 diabetes mellitus." This invention focuses on compositions comprising glucan-encapsulated siRNA directed against a region of the gene encoding the human CB1 receptor. It aims to treat type 2 diabetes mellitus in human subjects. Additionally, she has developed methods for administering these compositions to effectively manage the condition. Another notable patent is "Encapsulated nanoparticles for nucleic acid delivery." This invention presents methods and compositions for delivering agents, such as gene silencing agents, to cells using yeast cell wall particles. These embodiments are particularly useful for delivering nucleic acids, like siRNAs, to target cells.
Career Highlights
Aouadi has worked with esteemed institutions, including the University of Massachusetts and the National Institutes of Health, a component of the US Department of Health & Human Services. Her research has significantly impacted the understanding and treatment of diabetes.
Collaborations
Some of her notable coworkers include Michael P Czech and Gary R Ostroff. Their collaborative efforts have contributed to advancing research in their respective fields.
Conclusion
Myriam Aouadi's innovative work in diabetes treatment and nucleic acid delivery showcases her dedication to improving healthcare solutions. Her patents reflect her commitment to scientific advancement and the potential for significant impact in medical therapies.